Kyoohyoung Rho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyoohyoung Rho has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alessio Innocenti
Neurofarba Department, University of Florence, Via Ugo Schiff 6, Polo Scientifico, Sesto Fiorentino, 50019 Firenze, Italy
1 shared publication - Claudiu Trandafir Supuran
Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, Sesto Fiorentino, Firenze, 50019, Italy
1 shared publication - Dae Gyu Kim
Medicinal Bioconvergence Research Center, College of Pharmacy and College of Medicine, Gangnam Severance Hospital, Yonsei University, Incheon 21983, Korea
1 shared publication - Hee Sook Lee
Medicinal Bioconvergence Research Center, College of Pharmacy, Seoul National University, Seoul, Korea
1 shared publication - Ji-Hyun Lee
Medicinal Bioconvergence Research Center, College of Pharmacy, Seoul National University, Seoul, Korea
1 shared publication - Ji-Tea Kim
Information Center for Bio-Pharmacological Network, Seoul National University, Suwon, Korea
1 shared publication
Latest Publications
- Open Access
- 2 July 2012
- Published by Springer Nature in BMC Systems Biology
- Vol. 6 (1) , 1-10
Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug
Background: The process of drug discovery and development is time-consuming and costly, and the probability of success is low. Therefore, there is rising interest in repositioning existing drugs for new medical indications. When successful, this process reduces the risk of failure and costs associated with de novo drug development. However, in many cases, new indications of existing drugs have been found serendipitously. Thus there is a clear need for establishment of rational methods for drug repositioning. Results: In this study, we have established a database we call “PharmDB” which integrates data associated with disease indications, drug development, and associated proteins, and known interactions extracted from various established databases. To explore linkages of known drugs to diseases of interest from within PharmDB, we designed the Shared Neighborhood Scoring (SNS) algorithm. And to facilitate exploration of tripartite (Drug-Protein-Disease) network, we developed a graphical data visualization software program called phExplorer, which allows us to browse PharmDB data in an interactive and dynamic manner. We validated this knowledge-based tool kit, by identifying a potential application of a hypertension drug, benzthiazide (TBZT), to induce lung cancer cell death. Conclusions: By combining PharmDB, an integrated tripartite database, with Shared Neighborhood Scoring (SNS) algorithm, we developed a knowledge platform to rationally identify new indications for known FDA approved drugs, which can be customized to specific projects using manual curation. The data in PharmDB is open access and can be easily explored with phExplorer and accessed via BioMart web service (http://www.i-pharm.org/, http://biomart.i-pharm.org/).
- 2 July 2012
- Published by Springer Nature in BMC Systems Biology
- Vol. 6 (1) , 1-10
Open AccessRational drug repositioning guided by an integrated pharmacological network of protein, disease and drug
Background: The process of drug discovery and development is time-consuming and costly, and the probability of success is low. Therefore, there is rising interest in repositioning existing drugs for new medical indications. When successful, this process reduces the risk of failure and costs associated with de novo drug development. However, in many cases, new indications of existing drugs have been found serendipitously. Thus there is a clear need for establishment of rational methods for drug repositioning. Results: In this study, we have established a database we call “PharmDB” which integrates data associated with disease indications, drug development, and associated proteins, and known interactions extracted from various established databases. To explore linkages of known drugs to diseases of interest from within PharmDB, we designed the Shared Neighborhood Scoring (SNS) algorithm. And to facilitate exploration of tripartite (Drug-Protein-Disease) network, we developed a graphical data visualization software program called phExplorer, which allows us to browse PharmDB data in an interactive and dynamic manner. We validated this knowledge-based tool kit, by identifying a potential application of a hypertension drug, benzthiazide (TBZT), to induce lung cancer cell death. Conclusions: By combining PharmDB, an integrated tripartite database, with Shared Neighborhood Scoring (SNS) algorithm, we developed a knowledge platform to rationally identify new indications for known FDA approved drugs, which can be customized to specific projects using manual curation. The data in PharmDB is open access and can be easily explored with phExplorer and accessed via BioMart web service (http://www.i-pharm.org/, http://biomart.i-pharm.org/).